Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01227005
Other study ID # W81XWH-07-1-0229
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 2011
Est. completion date December 2012

Study information

Verified date May 2018
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposal will assess if patients who require massive transfusion can be accurately predicted early after emergency department arrival and assess if the use of stored whole blood during initial resuscitation will reduce transfusion needs compared to transfusion with component therapy and thus improve outcome.


Description:

Background: The acquired coagulopathy of trauma is responsible for a large percentage of early deaths in civilian trauma practice and is a major cause of battlefield mortality. Widespread recognition has provided a rationale for fundamental changes in the initial management of severely injured patients through prevention of hypothermia, damage control surgery, massive transfusion protocols and early triage to intensive care units for optimized resuscitation. Despite these major advances, hemorrhage remains a leading cause of early death in both civilian trauma and military combat casualty care. However, it is unclear how early whole blood will affect coagulopathy in this cohort of patients as compared to the current standard of care. Objective/Hypothesis: The proposal will assess if patients who require massive transfusion can be accurately predicted early after emergency department arrival and assess if the use of stored whole blood during initial resuscitation will reduce transfusion needs compared to transfusion with component therapy and thus improve outcome.

Study Design: As a first step in testing this hypothesis, we will test commonly utilized point of care analysis devices and determine their reliability in predicting transfusion requirements in severely injured trauma patients within 20 minutes after arrival in the emergency department. Furthermore, we will prospectively randomize severely injured patients who require a blood transfusion to receive either stored whole blood and pooled platelets or component therapy (packed red blood cells, fresh frozen plasma, and platelets, our current standard of care) and compare the ability of stored whole blood to reduce transfusion needs and improve clinical outcomes.

Relevance: Severe uncontrollable coagulopathy in major trauma patients continues to be a major determinant of trauma mortalities. The proposed effort aims to provide an early, coagulopathy-based prediction model to identify patients at risk for massive transfusion. Moreover, our proposal intends to evaluate early stored whole blood transfusion in this at risk patient population and determine stored whole blood's ability to prevent or control severe coagulopathy compared to standard transfusion care.


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date December 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

1. 18 years of age or older.

2. Meet Code 3 status; Code 3 is determined by the following criteria (Patients must meet at least one of the following physiologic and/or anatomic criteria):

- Physiologic criteria indicating high risk or life threatening injuries

- GCS <10 (Glasgow Coma Scale)

- SBP <90 (Systolic blood pressure)

- RR <10 or >29 (Respiratory rate)

- HR >120 (Heart rate)

- intubated

- Base Deficit > 6

- Anatomic criteria indicating high risk or life threatening injuries

- Any penetrating injury to torso, groin, or neck

- Amputation proximal to the ankle or wrist

- Uncontrolled external hemorrhage

- Two or more long bone fractures

- Pelvic fracture

- Paraplegia or quadriplegia

- Combination trauma with burns = 20% BSA (body surface area)

3. Demonstrate evidence of blood loss due to injury, requiring transfusion in the ED.

Exclusion Criteria:

1. Death thought to be imminent, suggesting a futile resuscitation effort

2. Known or assumed religious objection to blood products

3. Do not resuscitate order in place

4. Women who present to the ED who are obviously pregnant.

5. Patients who appear to the ED wearing the ?opt-out? bracelet provided at the community consultation.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Transfusion of blood products
The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).

Locations

Country Name City State
United States Memorial Hermann Hospital - Texas Medical Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston U.S. Army Medical Research and Materiel Command

Country where clinical trial is conducted

United States, 

References & Publications (5)

Erber WN, Tan J, Grey D, Lown JA. Use of unrefrigerated fresh whole blood in massive transfusion. Med J Aust. 1996 Jul 1;165(1):11-3. — View Citation

Grosso SM, Keenan JO. Whole blood transfusion for exsanguinating coagulopathy in a US field surgical hospital in postwar Kosovo. J Trauma. 2000 Jul;49(1):145-8. — View Citation

Ledgerwood AM, Lucas CE. A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile. J Trauma. 2003 May;54(5 Suppl):S68-74. Review. — View Citation

Mohr R, Martinowitz U, Lavee J, Amroch D, Ramot B, Goor DA. The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg. 1988 Oct;96(4):530-4. — View Citation

Oberman HA. The indications for transfusion of freshly drawn blood. JAMA. 1967 Jan 9;199(2):93-7. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Units of Blood Products Required During the First 24 Hours After Emergency Department Admission Compare the ability of whole blood to reduce initial 24-hour transfusion requirements as compared to component therapy (red blood cells, plasma, and platelet units) first 24 hours after ED admission
Secondary 24-hour Mortality Mortality rate at 24 hours after arrival First 24 hours after ED admission
Secondary 30-day Mortality Evaluate 30-day mortality among those receiving whole blood compared to those receiving component therapy first 30 days after ED admission
See also
  Status Clinical Trial Phase
Completed NCT02100163 - Virtual Reality Pain Control Orthopedic Trauma N/A